The estimated Net Worth of Stuart Poulton is at least 303 千$ dollars as of 30 July 2024. Stuart Poulton owns over 2,883 units of Karyopharm Therapeutics Inc stock worth over 241,705$ and over the last 2 years Stuart sold KPTI stock worth over 60,901$.
Sign up
Stuart Poulton KPTI stock SEC Form 4 insiders trading
Stuart has made over 5 trades of the Karyopharm Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Stuart sold 2,883 units of KPTI stock worth 3,056$ on 30 July 2024.
The largest trade Stuart's ever made was selling 22,466 units of Karyopharm Therapeutics Inc stock on 29 February 2024 worth over 26,510$. On average, Stuart trades about 4,989 units every 66 days since 2023. As of 30 July 2024 Stuart still owns at least 326,628 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Stuart Poulton stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Stuart Poulton's mailing address?
Stuart's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Insiders trading at Karyopharm Therapeutics Inc
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over 149,223,596$ worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth 10,312,371$ . The most active insiders traders include Deepika Pakianathan、Ltd Czernik Marcin Hadjimic...、Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of 26,350$. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth 2,859$.
What does Karyopharm Therapeutics Inc do?
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
What does Karyopharm Therapeutics Inc's logo look like?
Complete history of Stuart Poulton stock trades at Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc executives and stock owners
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ran Frenkel,
Chief Development Operations Officer -
Michael Kauffman,
Co-Founder, Chief Executive Officer and Director -
Sharon Shacham,
President, Chief Scientific Officer -
Christopher Primiano,
Executive Vice President, Chief Business Officer, General Counsel and Secretary -
Dr. Michael G. Kauffman M.D., Ph.D.,
Co-Founder, Sr. Clinical Advisor & Director -
Dr. Michael G. Kauffman,
Co-Founder, Sr. Clinical Advisor & Director -
Dr. Sharon Shacham M.B.A., Ph.D.,
Co-Founder & Chairman of Scientific Advisory Board -
Dr. Sharon Shacham,
Co-Founder, Chief Scientific Officer & Chairman of Scientific Advisory Board -
Michael P. Mason CPA, M.B.A.,
Sr. VP, CFO & Treasurer -
Mansoor Mirza,
Director and Clinical Advisor -
Barry Greene,
Lead Independent Director -
Deepa Pakianathan,
Independent Director -
Garen Bohlin,
Independent Director -
Dr. Mansoor Raza Mirza M.D.,
Clinical Consultant, Member of Scientific Advisory Board & Independent Director -
Mikael Dolsten,
Independent Director -
Dr. Mansoor Raza Mirza,
Clinical Consultant, Member of Scientific Advisory Board & Director -
Richard A. Paulson M.B.A.,
Pres, CEO & Director -
Richard Paulson,
Independent Director -
Christy Oliger,
Director -
Perry Monaco,
Senior Vice President of Sales -
Jatin Shah,
Executive Vice President, Chief Medical Officer -
Tanya Lewis,
Executive Vice President, Chief Regulatory Officer and Quality Officer -
Michael Mason,
Chief Financial Officer, Senior Vice President, Treasurer -
James Accumanno J.D.,
Chief Compliance Officer -
Elhan Webb C.F.A.,
Sr. VP of Investor Relations -
Lisa Meletta J.D.,
VP of Legal & Chief Compliance Officer -
Michael J. Mano J.D.,
Sr. VP, Gen. Counsel & Sec. -
Pierre S. Sayad M.S., Ph.D.,
VP of Global Medical & Scientific Affairs -
Cameron Peters,
VP of Fin., Assistant Treasurer & Principal Accounting Officer -
Ran Frenkel R.Ph., RPh,
Exec. VP & Chief Devel. Officer -
Zhen Su,
-
Carsten Thiel,
Director -
Kenneth E Weg,
Director -
J. Scott Garland,
Director -
Justin A Renz,
EVP, CFO & Treasurer -
Michael Falvey,
EVP, CFO & Treasurer -
Peter Honig,
Director -
Anand Varadan,
EVP, Chief Commercial Officer -
Cameron Peters,
VP of Finance -
Marcin Hadjimichael Andreas...,
-
Paul Brannelly,
SVP, FIN & ADMIN, SEC & TRES -
Ltd Czernik Marcin Hadjimic...,
-
Ltd Czernik Marcin Hadjimic...,
-
John Demaree,
Chief Commercial Officer -
Deepika Pakianathan,
-
Chen Schor,
-
Stephen Mitchener,
SVP, Chief Business Officer -
Michael Mano,
SVP, General Counsel&Secretary -
Sohanya Roshan Cheng,
EVP & Chief Commercial Officer -
Stuart Poulton,
EVP, Chief Development Officer -
Reshma Rangwala,
EVP & Chief Medical Officer